Xeris Pharmaceuticals Inc., a Chicago-based specialty pharma firm, said it entered an amended and restated loan and security agreement with Oxford Finance LLC and Silicon Valley Bank, which increases the borrowing base from $45 million to up to $85 million, subject to certain conditions, and extends the maturity date of the debt to as late as June 2024, if the second tranche is drawn.